IL6 and head and neck squamous cell carcinoma: Without IFN-γ stimulation, the suppression of IL-6 production, which could be interpreted as a beneficial response of HNSCC to treatment, was displayed by 11, 10, and 12 out of 23 samples (for pembrolizumab, cetuximab, and pembrolizumab plus cetuximab, respectively).